ExodusPoint Capital Management LP acquired a new position in Azenta, Inc. (NASDAQ:AZTA – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 53,250 shares of the company’s stock, valued at approximately $2,376,000. ExodusPoint Capital Management LP owned about 0.08% of Azenta as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in AZTA. EverSource Wealth Advisors LLC lifted its holdings in shares of Azenta by 321.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 485 shares of the company’s stock worth $28,000 after acquiring an additional 370 shares during the last quarter. Quadrant Capital Group LLC increased its stake in shares of Azenta by 82.8% in the fourth quarter. Quadrant Capital Group LLC now owns 817 shares of the company’s stock worth $48,000 after buying an additional 370 shares during the period. Van ECK Associates Corp increased its stake in shares of Azenta by 41.2% in the fourth quarter. Van ECK Associates Corp now owns 1,516 shares of the company’s stock worth $88,000 after buying an additional 442 shares during the period. Belpointe Asset Management LLC purchased a new position in shares of Azenta in the fourth quarter worth $113,000. Finally, ETF Managers Group LLC purchased a new position in shares of Azenta in the first quarter worth $132,000. 99.08% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several research analysts recently commented on the stock. Raymond James initiated coverage on shares of Azenta in a research note on Tuesday, July 18th. They issued a “market perform” rating on the stock. TheStreet downgraded shares of Azenta from a “c-” rating to a “d” rating in a research report on Wednesday, May 10th. Stephens boosted their price objective on shares of Azenta from $45.00 to $55.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 9th. Finally, Needham & Company LLC upped their target price on shares of Azenta from $55.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $64.50.
Insider Buying and Selling
In related news, insider David C. Gray sold 4,311 shares of the company’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $57.24, for a total value of $246,761.64. Following the transaction, the insider now owns 87,919 shares in the company, valued at approximately $5,032,483.56. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 1.67% of the stock is currently owned by company insiders.
Azenta Price Performance
NASDAQ:AZTA opened at $56.43 on Friday. The firm’s 50-day moving average price is $49.15 and its 200-day moving average price is $45.44. The company has a market capitalization of $3.40 billion, a PE ratio of -108.52 and a beta of 1.57. Azenta, Inc. has a 1-year low of $36.01 and a 1-year high of $63.60.
Azenta (NASDAQ:AZTA – Get Free Report) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.16. The company had revenue of $165.95 million for the quarter, compared to analysts’ expectations of $153.42 million. Azenta had a negative net margin of 6.09% and a positive return on equity of 0.84%. Azenta’s revenue was up 25.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.12 EPS. Equities analysts anticipate that Azenta, Inc. will post 0.07 EPS for the current fiscal year.
Azenta Company Profile
Azenta, Inc provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows.
- Five stocks we like better than Azenta
- How to Invest in Cannabis, Step by Step
- 3 Takeaways from the August Inflation Report
- What is a Mid Cap Stock? How to Invest
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- What is a Low P/E Ratio and What Does it Tell Investors?
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.